BrainsWay to Ring NASDAQ Closing Bell to Highlight May as Mental Health Awareness Month
03 mai 2021 08h00 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, May 03, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers
29 avr. 2021 09h03 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, April 29, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive treatment of brain...
BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder
26 avr. 2021 07h30 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, April 26, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS)
14 avr. 2021 09h03 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...
BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights
24 mars 2021 16h06 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, March 24, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
01 mars 2021 07h00 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, March 01, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of...
BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares
23 févr. 2021 08h30 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of...
BrainsWay Ltd. Announces Proposed Public Offering of American Depositary Shares
22 févr. 2021 16h02 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, Feb. 22, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of...
BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales
16 févr. 2021 07h30 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive...
BrainsWay Reports Preliminary Record Fourth Quarter Revenue and Full-Year 2020 Financial Results
16 févr. 2021 07h00 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of...